HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.

Abstract
The current pharmacological therapies for the treatment of Parkinson's disease are mostly inadequate and recent, improved therapeutic agents are required. Two important molecular targets for the design of anti-parkinsonian therapeutic compounds are the adenosine A2A receptor and the enzyme, monoamine oxidase (MAO) B. Adenosine A2A receptor antagonists are a relatively new class of anti-parkinsonian agents, which act by potentiating dopamine-mediated neurotransmission via dopamine D2 receptors. MAO-B inhibitors are established therapy of Parkinson's disease and inhibit the MAO-B-catalysed metabolism of dopamine in the brain. This conserves reduced dopamine stores and extends the action of dopamine. A2A antagonism and MAO-B inhibition have also been associated with neuroprotective effects, further establishing roles for these classes of compounds in Parkinson's disease. Interestingly, caffeine, a known adenosine receptor antagonist, has been recently considered as a lead compound for the design and discovery of A2A antagonists and MAO-B inhibitors. This review summarizes the recent efforts to discover caffeinederived MAO-B inhibitors. The design of caffeine-derived A2A antagonists has been extensively reviewed previously. The prospect of discovering dual-target-directed compounds that act at both targets is also evaluated. Compounds that block the activation and function of both A2A receptors and MAO-B may have a synergistic effect in the treatment of patients with Parkinson's disease.
AuthorsJacobus P Petzer, Anel Petzer
JournalCurrent medicinal chemistry (Curr Med Chem) Vol. 22 Issue 8 Pg. 975-88 ( 2015) ISSN: 1875-533X [Electronic] United Arab Emirates
PMID25544641 (Publication Type: Journal Article, Review)
Chemical References
  • Adenosine A2 Receptor Antagonists
  • Monoamine Oxidase Inhibitors
  • Caffeine
  • Monoamine Oxidase
Topics
  • Adenosine A2 Receptor Antagonists (pharmacology, therapeutic use)
  • Animals
  • Caffeine (analogs & derivatives, pharmacology, therapeutic use)
  • Drug Design
  • Humans
  • Monoamine Oxidase (metabolism)
  • Monoamine Oxidase Inhibitors (pharmacology, therapeutic use)
  • Parkinson Disease (drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: